尼拉帕利联合帕博利珠单抗维持治疗晚期或转移性NSCLC的III期研究(ZEAL-1L)
ZEAL-1L是一项随机双盲III期研究,评估尼拉帕利联合帕博利珠单抗对比安慰剂联合帕博利珠单抗在晚期或转移性NSCLC(无已知可靶向驱动基因改变)维持治疗中的疗效。主要终点为一线化疗联合帕博利珠单抗后达到完全或部分缓解(CR/PR)患者的盲法独立中心评审无进展生存期(PFS)。结果显示CR/PR人群两组中位PFS均为5.55个月(HR 1.00,95%CI 0.79-1.27,单侧P=0.502),联合尼拉帕利未改善疗效,未发现新安全性信号。
要点
- 在CR/PR人群中,尼拉帕利联合帕博利珠单抗对比安慰剂联合帕博利珠单抗的中位PFS均为5.55个月,HR 1.00(95%CI 0.79-1.27)。
- 因主要终点未达统计学显著性,预设的序贯检验终止,关键次要终点未进行正式检验。
- 尼拉帕利联合组最常见的≥3级治疗相关不良事件为血液学毒性(贫血、血小板减少、中性粒细胞减少)。
核心结论
- 在晚期或转移性NSCLC患者中,帕博利珠单抗维持治疗基础上加用尼拉帕利未改善疗效,未发现新安全性信号。
研究设计与样本
- 随机、双盲、III期研究(ZEAL-1L,NCT04475939),纳入无已知可靶向驱动基因改变的晚期或转移性鳞状或非鳞状NSCLC成人患者。
- 患者按1:1随机接受尼拉帕利联合帕博利珠单抗或安慰剂联合帕博利珠单抗维持治疗;尼拉帕利每日口服300或200 mg,帕博利珠单抗200 mg静脉每3周一次。
主要发现
- CR/PR人群中,尼拉帕利联合组与安慰剂联合组的中位PFS均为5.55个月(HR 1.00,95%CI 0.79-1.27,单侧P=0.502)。
- 因主要终点未达统计学显著性,ITT人群盲法独立中心评审PFS、CR/PR及ITT人群总生存期、中枢神经系统进展时间等关键次要终点未进行正式检验。
- 尼拉帕利联合组最常见的≥3级治疗相关不良事件为血液学毒性,包括贫血、血小板减少和中性粒细胞减少。
临床怎么用
- 对于一线化疗联合帕博利珠单抗后达到CR/PR的晚期或转移性NSCLC患者,不推荐在帕博利珠单抗维持治疗基础上加用尼拉帕利。
- 若临床研究中涉及尼拉帕利联合免疫维持治疗,需关注血液学毒性监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This randomized, double-blind, phase 3 study evaluated niraparib plus pembrolizumab as maintenance therapy for patients with advanced or metastatic NSCLC (NSCLC; ZEAL-1L, ClinicalTrials.gov identifier: NCT04475939). METHODS: Adults with advanced or metastatic squamous or nonsquamous NSCLC without a known targetable driver alteration were randomly assigned (1:1) to receive niraparib plus pembrolizumab or placebo plus pembrolizumab as maintenance therapy. Niraparib was given as a daily oral dose of 300 or 200 mg, and intravenous pembrolizumab was administered at 200 mg every 3 weeks. The primary end point was progression-free survival (PFS) by blinded independent central review in patients with a complete or partial response (CR/PR) to front-line chemotherapy combined with pembrolizumab. Hierarchical testing was performed on the primary and key secondary end points in a prespecified sequential order; formal testing was stopped if any end point failed to reach statistical significance. RESULTS: Patients comprising the intent-to-treat (ITT) population (n = 666) were randomly assigned to niraparib plus pembrolizumab (n = 331) or placebo-plus-pembrolizumab (n = 335) therapy. The median PFS for the CR/PR population (n = 200 receiving niraparib plus pembrolizumab; n = 201 receiving placebo-plus-pembrolizumab) was 5.55 months in both treatment arms (hazard ratio, 1.00; 95% confidence interval: 0.79-1.27; 1-sided p = 0.502). Key secondary end points of PFS by blinded independent central review in the ITT population, overall survival in the CR/PR and ITT populations, and time to progression in the central nervous system were not formally tested. The most common grade 3 or higher treatment-related adverse events in the niraparib plus pembrolizumab arm were hematologic (anemia, thrombocytopenia, and neutropenia). CONCLUSION: The addition of niraparib to pembrolizumab for maintenance therapy in patients with advanced or metastatic NSCLC did not result in improved efficacy; no new safety signals were detected. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov Identifier: NCT04475939.
引用
- Ramalingam SS, Velcheti V, Altan M, et al. Phase III Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced or Metastatic NSCLC (ZEAL-1L). J Thorac Oncol. 2026. PMID: 42431263. doi:10.1016/j.jtho.2026.104087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。